Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Targeting integrins for cancer therapy - disappointments and opportunities

Autor: Bergonzini, C., Kroese, K., Zweemer, J.M., Danen, E.H.J.

Publikováno v: Frontiers in Cell and Developmental Biology, 10:863850. Frontiers Media SA

Integrins mediate adhesive interactions between cells and their environment, including neighboring cells and extracellular matrix (ECM). These heterodimeric transmembrane receptors bind extracellular ligands with their globular head domains and conne

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c95b060c36c92c670fe350c69a5b75e5
https://hdl.handle.net/1887/3420582

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer.

Autor: Kortleve D; Laboratory of Tumor Immunology, Erasmus MC, Rotterdam, the Netherlands.; Department of Medical Oncology, Erasmus MC, Rotterdam, the Netherlands., Hammerl D; Laboratory of Tumor Immunology, Erasmus MC, Rotterdam, the Netherlands.; Department of Medical Oncology, Erasmus MC, Rotterdam, the Netherlands.; Pan Cancer T BV, Rotterdam, the Netherlands., van Brakel M; Laboratory of Tumor Immunology, Erasmus MC, Rotterdam, the Netherlands.; Department of Medical Oncology, Erasmus MC, Rotterdam, the Netherlands., Wijers R; Laboratory of Tumor Immunology, Erasmus MC, Rotterdam, the Netherlands.; Department of Medical Oncology, Erasmus MC, Rotterdam, the Netherlands., Roelofs D; Pan Cancer T BV, Rotterdam, the Netherlands., Kroese K; Pan Cancer T BV, Rotterdam, the Netherlands., Timmermans MM; Department of Medical Oncology, Erasmus MC, Rotterdam, the Netherlands., Liao CY; Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands., Huang S; Laboratory of Tumor Immunology, Erasmus MC, Rotterdam, the Netherlands.; Department of Medical Oncology, Erasmus MC, Rotterdam, the Netherlands., Trapman-Jansen A; Department of Medical Oncology, Erasmus MC, Rotterdam, the Netherlands., Foekens R; Department of Medical Oncology, Erasmus MC, Rotterdam, the Netherlands., Michaux J; Department of Oncology, UNIL CHUV, Ludwig Institute for Cancer Research, Lausanne, Switzerland.; Agora Cancer Research Centre, Lausanne, Switzerland., de Beijer MTA; Laboratory of Tumor Immunology, Erasmus MC, Rotterdam, the Netherlands.; Department of Medical Oncology, Erasmus MC, Rotterdam, the Netherlands.; Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, the Netherlands., Buschow SI; Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, the Netherlands., Demmers JAA; Proteomics Center, Erasmus MC, Rotterdam, the Netherlands., Kok M; Division of Tumor Biology & Immunology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Danen EHJ; Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands., Bassani-Sternberg M; Department of Oncology, UNIL CHUV, Ludwig Institute for Cancer Research, Lausanne, Switzerland.; Agora Cancer Research Centre, Lausanne, Switzerland., Martens JWM; Department of Medical Oncology, Erasmus MC, Rotterdam, the Netherlands., Abbott RJM; Pan Cancer T BV, Rotterdam, the Netherlands., Debets R; Laboratory of Tumor Immunology, Erasmus MC, Rotterdam, the Netherlands.; Department of Medical Oncology, Erasmus MC, Rotterdam, the Netherlands.

Publikováno v: Cancer discovery [Cancer Discov] 2024 Dec 02; Vol. 14 (12), pp. 2450-2470.